The Cooper Companies, Inc. (NASDAQ:COO) Receives $117.00 Average PT from Analysts

Shares of The Cooper Companies, Inc. (NASDAQ:COO) have earned a consensus rating of “Moderate Buy” from the twelve research firms that are currently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $117.00.

COO has been the topic of a number of analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research report on Friday, December 6th. Robert W. Baird boosted their price target on shares of Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, August 29th. Citigroup reduced their price objective on shares of Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, December 6th. Stifel Nicolaus reiterated a “buy” rating and set a $115.00 target price (up previously from $110.00) on shares of Cooper Companies in a research report on Thursday, August 29th. Finally, StockNews.com cut Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th.

Cooper Companies Trading Down 0.5 %

NASDAQ COO opened at $91.93 on Friday. Cooper Companies has a one year low of $84.76 and a one year high of $112.38. The firm has a market cap of $18.35 billion, a PE ratio of 47.14, a P/E/G ratio of 2.52 and a beta of 0.97. The firm’s fifty day moving average is $102.46 and its two-hundred day moving average is $98.90. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.00 by $0.04. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same period in the prior year, the business earned $0.87 EPS. The firm’s revenue was up 9.8% compared to the same quarter last year. Analysts expect that Cooper Companies will post 3.98 earnings per share for the current year.

Institutional Investors Weigh In On Cooper Companies

Large investors have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC lifted its holdings in Cooper Companies by 2.8% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,797 shares of the medical device company’s stock valued at $593,000 after purchasing an additional 184 shares in the last quarter. Blue Trust Inc. raised its position in shares of Cooper Companies by 112.7% in the second quarter. Blue Trust Inc. now owns 553 shares of the medical device company’s stock valued at $48,000 after buying an additional 293 shares during the last quarter. Raymond James & Associates lifted its stake in shares of Cooper Companies by 4.4% during the second quarter. Raymond James & Associates now owns 647,106 shares of the medical device company’s stock valued at $56,492,000 after buying an additional 27,442 shares during the period. First Horizon Advisors Inc. boosted its position in Cooper Companies by 4.8% during the second quarter. First Horizon Advisors Inc. now owns 2,709 shares of the medical device company’s stock worth $236,000 after acquiring an additional 125 shares during the last quarter. Finally, Fifth Third Bancorp grew its stake in Cooper Companies by 6.3% in the 2nd quarter. Fifth Third Bancorp now owns 8,465 shares of the medical device company’s stock worth $739,000 after acquiring an additional 502 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.